Skip to main content
SpringerLink
Log in

Pharmacokinetics of Epoetin (Recombinant Human Erythropoietin) after Long Term Therapy in Patients Undergoing Haemodialysis and Haemofiltration

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

After long term therapy with epoetin (recombinant human erythropoietin) 17 patients with end-stage renal disease (ESRD) were studied in 3 groups to assess pharmacokinetics during the intertreatment interval and during haemofiltration and dialysis treatment. Epoetin was measured by radioimmunoassay. After an intravenous bolus of epoetin 150 U/kg bodyweight, the half-life was 7.7h, steady-state volume of distribution was 0.066 L/kg and total plasma clearance was 5.4 ml/min. The mean steady-state serum concentration during multiple-dose administration was 656 U/L. The drug was not eliminated by haemofiltration or dialysis. Long term treatment of ESRD patients with epoetin does not significantly alter the pharmacokinetic profile of the drug. Epoetin dosage adjustment or substitution after haemofiltration and dialysis is not necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Akahane K, Tojo A, Fukamachi H, Kitamura T, Saito T, et al. Binding of iodinated erythropoietin to rat bone marrow cells under normal and anemic conditions. Experimental Hematology 17: 177–182, 1989

    PubMed  CAS  Google Scholar 

  • Brockmöller J, Köchling J, Scigalla P, Weber W, Roots I, et al. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. European Journal of Pharmacology 183: 2391–2392, 1990

    Article  Google Scholar 

  • Brockmöller J, Köchling J, Weber W, Looby M, Roots I, et al. The pharmacokinetics and pharmacydynamics of recombinant human erythropoietin in haemodialysis patients. British Journal of Clinical Pharmacology 34: 499–508, 1992

    PubMed  Google Scholar 

  • Cotes PM, Pippard MJ, Reid CDL, Winearls CG, Oliver DO, et al. Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. Quarterly Journal of Medicine 70: 113–137, 1989

    CAS  Google Scholar 

  • Davis JM, Arakawa T, Strickland TW, Yphantis DA. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 26: 2633–2638, 1987

    Article  PubMed  CAS  Google Scholar 

  • DeSpain M, Cheung A. Binding of recombinant erythropoietin (EPO) to hemodialysis membranes. Kidney International 37: 293, 1990

    Google Scholar 

  • Eckardt K-U, Kurtz A, Hirth P, Scigalla P, Wieczorek L, et al. Evaluation of the stability of human erythropoietin in samples for radioimmunoassay. Klinische Wochenschrift 66: 241–245, 1988

    Article  PubMed  CAS  Google Scholar 

  • Egrie JC, Eschbach JW, McGuire T, Adamson JW. Pharmacokinetics of recombinant human erythropoietin (rHuEpo) administered to hemodialysis (HD) patients. Kidney International 33: 262, 1988

    Google Scholar 

  • Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. New England Journal of Medicine 316: 73–78, 1987

    CAS  Google Scholar 

  • Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris M, et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clinical Pharmacology and Therapeutics 47: 557–564, 1990

    Article  PubMed  Google Scholar 

  • Gibson TP. Influence of renal disease on pharmacokinetics. In Evans et al. (Eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, pp. 32–56, San Francisco, Applied Therapeutics, 1980

    Google Scholar 

  • Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanab M, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clinical Pharmacology and Therapeutics 50: 702–712, 1991

    Article  PubMed  CAS  Google Scholar 

  • Heinzel G, Woloszczak R, Thomann P. (Eds) TopFit (Version 2.0): pharmacokinetic and pharmacodynamic data analysis system for the PC, G Fischer, Stuttgart/Jena/New York, 1993

    Google Scholar 

  • Kampf D, Eckardt KU, Fischer HC, Schmalisch C, Ehmer B, et al. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron 61: 393–398, 1992

    Article  PubMed  CAS  Google Scholar 

  • Kindler J, Eckardt K-U, Ehmer B, Jandeleit K, Kurtz A, et al. Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrology Dialysis Transplantation 4: 345–349, 1989

    CAS  Google Scholar 

  • Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, et al. Recombinant human erythropoietin treatment in pre-dialysis patients: a double-blind placebo-controlled trial. Annals of Internal Medicine 110: 108–114, 1989

    PubMed  CAS  Google Scholar 

  • Maxwell AP, Douglas JF, Afrasiabi M, Lappin TRJ, Bridges JM. Erythropoietin pharmacokinetics and red cell metabolism in haemodialysis patients. Nephrology Dialysis Transplantation 4: 476, 1989

    Google Scholar 

  • Mufson RA, Gesner TG. Binding and internalization of recombinant human erythropoietin in murine erythroid precursor cells. Blood 69: 1485–1490, 1987

    PubMed  CAS  Google Scholar 

  • Muirhead N, Keown PA, Slaughter D, Mazaheri R, Jevnikar AM, et al. Recombinant human erythropoietin in the anaemia of chronic renal failure: a pharmacokinetic study. Nephrology Dialysis Transplantation 3: 499, 1988

    Google Scholar 

  • Neumayer HH, Brockmöller J, Fritschka E, Roots I, Scigalla P, et al. Pharmacokinetics of recombinant human erythropoietin after sc administration and in long-term iv treatment in patients on maintenance haemodialysis. In Baldamus et al. (Eds) Erythropoietin: from molecular structure to clinical application, Contributions to Nephrology, Vol. 76, pp. 131–142, Karger, Basel, 1989

    CAS  Google Scholar 

  • Nielsen OJ. Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients. Pharmacology and Toxicology 66: 83–86, 1990

    Article  PubMed  CAS  Google Scholar 

  • Salmonson T, Danielson BG, Grahnén A, Wikström B. Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure. Journal of Internal Medicine 228: 53–57, 1990a

    Article  PubMed  CAS  Google Scholar 

  • Salmonson T, Wikström B, Danielson BG. Pharmacokinetics of intravenous recombinant erythropoietin (r-EPO) prior to and during long-term treatment in haemodialysis patients. Nephrology Dialysis Transplantation 5: 742, 1990b

    Google Scholar 

  • Sawada K, Krantz SB, Sawyer ST, Civin CI. Quantitation of specific binding of erythropoietin to human erythroid colony-forming cells. Journal of Cellular Physiology 137: 337–345, 1988

    Article  PubMed  CAS  Google Scholar 

  • Stockenhuber F, Loibl U, Gottsauner-Wolf M, Jahn C, Manker W, et al. Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Nephron 59: 399–402, 1991

    Article  PubMed  CAS  Google Scholar 

  • Takeda F, Momose T, Ubukata E, Morio K, Sano M, et al. Pharmacokinetics of recombinant human erythropoietin in patients with chronic renal failure. XIth International Congress of Nephrology 1990, Tokyo, Abstract No. 293 A, 1990

    Google Scholar 

  • Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2: 1175–1178, 1986

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine II, Technical University of Aachen, Pauwelsstrasse 30, D-52057, Aachen, Federal Republic of Germany

    Ulrich Gladziwa, Ulrich Klotz, Kerstin Bäumer, Ralph Zollinger, Helmut Mann & Heinz-Günter Sieberth

  2. Dr Margarete-Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Federal Republic of Germany

    Ulrich Gladziwa, Ulrich Klotz, Kerstin Bäumer, Ralph Zollinger, Helmut Mann & Heinz-Günter Sieberth

Authors
  1. Ulrich Gladziwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Klotz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kerstin Bäumer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ralph Zollinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Helmut Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Heinz-Günter Sieberth
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gladziwa, U., Klotz, U., Bäumer, K. et al. Pharmacokinetics of Epoetin (Recombinant Human Erythropoietin) after Long Term Therapy in Patients Undergoing Haemodialysis and Haemofiltration. Clin-Pharmacokinet 25, 145–153 (1993). https://doi.org/10.2165/00003088-199325020-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199325020-00007

Keywords

Search

Navigation